• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

The TH3RESA study: TDM-1 doubles progression free survival in HER-2 positive refractory metastatic breast cancer.

0
  • by karen
  • in Oncology · Video
  • — 19 Nov, 2013

AMSTERDAM—Women with HER-2 positive metastatic breast cancer had significantly improved time to progression with fewer side effects after treatment with the antibody-drug conjugate T-DM1 compared to conventional therapies in the phase three TH3RESA study presented to the 2013 European Cancer Congress.
Outcome data were announced from 602 women — selected for study because they had disease progression despite treatment with a taxane and at least two HER2-directed therapies (including trastuzumab and lapatinib) — who were randomised to treatment with either: a regimen of their physicians choice or T-DM1 — the drug combining trastuzumab with emtansine.
Professor Hans Wildiers MD, PhD from the University Hospitals Multidisciplinary Breast Centre in Leuven, Belgium, described the combination drug as a ‘silver bullet’ — having a cancer-seeking arm linked to a cell killing molecule. He said the data reaffirm the potential of T-DM1 as a treatment for HER2-positive metastatic breast cancer — demonstrating that the drug has the potential to be a new treatment paradigm for this group of patients who currently have few options.

Share

Tags: ECC 2013 AmsterdamHER2HER2-positive metastatic breast cancerimmuno-conjugatemetastatic breast cancerProfessor Hans Wildiersprogressive diseaseT-DM1targeted cancer drugTH3RESATrastuzumab-emntansine

You may also like...

  • Hormone Refractory Prostate Cancer: Increased Progression-Free Survival With Satraplatin and Prednisone Hormone Refractory Prostate Cancer: Increased Progression-Free Survival With Satraplatin and Prednisone 1 Feb, 2008
  • Francesco Lo Coco Acute promyelocytic leukaemia: arsenic better than chemotherapy to combine with retinoic acid? 18 Dec, 2012
  • Oncology Times Broadcast News with the Audio Journal of Oncology – Bilateral Prophylactic Mastectomy For DCIS Oncology Times Broadcast News with the Audio Journal of Oncology – Bilateral Prophylactic Mastectomy For DCIS 6 Apr, 2009
  • Endothelin Antagonist Keeps Patients with Hormone Refractory Prostate Cancer Alive Longer Endothelin Antagonist Keeps Patients with Hormone Refractory Prostate Cancer Alive Longer 2 Nov, 2007

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Disease-free survival doubles for patients treated with immunoconjugate TDM-1 for their HER-2 positive metastatic breast cancers
  • Next story Prostate cancer screening: French study finds more harm than good from PSA testing
  • News

    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic…
    • Nuclear War: The Facts Today
    • Women With DCIS Live Longer Than General Population
    • Second-Generation ALK Inhibitor = Longer PFS in ALK+…
    • Which High-Risk Prostate Cancers Need Multimodality…
  • Home
  • Oncology
  • The TH3RESA study: TDM-1 doubles progression free survival in HER-2 positive refractory metastatic breast cancer.

© COPYRIGHT 2013 AUDIOMEDICA.COM.